Generic Name and Formulations:
Zileuton 600mg; tabs.
Chiesi USA, Inc.
Indications for ZYFLO:
Prophylaxis and chronic treatment of asthma.
Swallow whole. Take with meals and at bedtime. 600mg four times daily; max: 2400mg/day.
Active liver disease. Persistent ALT elevations ≥3xULN.
Not for primary treatment of acute attacks. Monitor liver function before initiating therapy, monthly for the 1st 3 months, every 2–3 months for the remainder of the year, and periodically thereafter (discontinue if signs/symptoms occur). History of liver disease. Alcohol consumption. Evaluate if neuropsychiatric events occur. Pregnancy (Cat.C). Nursing mothers: not recommended.
Potentiates theophylline (reduce dose of theophylline by about ½). Potentiates warfarin, propranolol (possibly other β-blockers); monitor and adjust doses. Monitor concomitant CYP3A4 inhibitors (eg, ketoconazole).
Sinusitis, pharyngolaryngeal pain, abdominal pain, nausea, dyspepsia, headache, rash, hypersensitivity, hepatotoxicity, upper respiratory tract infection, myalgia; neuropsychiatric events (eg, sleep disorders, behavior changes).
Hepatic (CYP1A2, CYP 2C9, CYP3A4).
Renal (major), fecal (minor).
Tabs, CR tabs—120
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- Feasibility of Clinical Production of Autologous NKG2D CAR-T
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline